Anavex Life Sciences Corp. (AVXL)
After hours:
| Previous Close | 6.36 |
| Open | 6.30 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 6.09 - 6.32 |
| 52 Week Range | 6.09 - 15.24 |
| Volume | |
| Avg. Volume | 833,425 |
| Market Cap | 513.014M |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.62 |
| Earnings Date | Nov 27, 2023 - Dec 01, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.75 |
GlobeNewswireAnavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Significant Reduction of Amyloid Beta Biomarkers of Alzheimer’s PathologyNEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders announced today that a follow-on analysis of the landmark Phase 2b/3 study to treat early Alzheimer’s disease with the investigational drug blarcamesine (ANA
- GlobeNewswire
Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Prof. Dr. Marwan N Sabbagh, MD, as Chairman of the Scientific Advisory Board. Pr
Simply Wall St.Anavex Life Sciences Corp. (NASDAQ:AVXL) Is Expected To Breakeven In The Near Future
With the business potentially at an important milestone, we thought we'd take a closer look at Anavex Life Sciences...
